Delivery Order SPE2DR25D1053-SPE2DR26FT873
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $13,862.79 to AmerisourceBergen Drug Corp for Zeposia 0.92 mg capsules (30-count) on July 24, 2025, with an ultimate completion date of August 14, 2025. The contract employs firm fixed-price pricing with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,739.52 to AmerisourceBergen Drug Corp for the supply of Zeposia 0.92 mg capsules (30-count packages) on November 7, 2025, with completion scheduled for December 2, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $13,862.79 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Zeposia 0.92 mg capsules (30-count units). This is a firm fixed-price contract with an ultimate completion date of August 20, 2025, and represents a non-competitive set-aside delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be performed and delivered from the company's Conshohocken,...
- The Defense Logistics Agency awarded a $13,862.82 firm fixed price delivery order to AmerisourceBergen Drug Corp on November 5, 2025, for the supply of Zeposia 0.92 mg capsules (30-count units). This non-set-aside competitive award is scheduled for completion by November 28, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement, fulfills this...
- The Defense Logistics Agency awarded a $13,862.79 delivery order to AmerisourceBergen Drug Corp for Zeposia 0.92 mg capsules (30-count units) on September 10, 2025, with an ultimate completion date of October 1, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's substantial...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $4,869.75 to supply Zeposia 0.92 mg capsules (30-count) with a firm fixed price structure. This non-competitive, competitively-awarded delivery order is set to complete by December 5, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Zeposia 0.92 mg capsules (30-count) with a ceiling value of $13,862.79. This firm fixed-price delivery order represents a non-competitive award and is scheduled for completion by August 29, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a leading pharmaceutical distributor, AmerisourceBergen maintains a...
- The Defense Logistics Agency awarded a delivery order valued at $4,620.94 to AmerisourceBergen Drug Corp for the supply of Zeposia 0.92 mg capsules (30-count package) under a firm fixed price arrangement. This non-competitive, non-set-aside delivery order was awarded on October 28, 2025, with an ultimate completion date of November 19, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, which serves as the company's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Zeposia 0.92 mg capsules (30-count units) with a contract value of $4,620.93. This non-competitive delivery order utilizes firm fixed pricing and is scheduled for completion by September 25, 2025. The award is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion global pharmaceutical support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for Zeposia 0.92 mg capsules (30-count units) under a firm fixed-price contract valued at $13,862.79. This non-set-aside competitive award, with an ultimate completion date of August 18, 2025, will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- SPE2DR25D1053Indefinite Delivery Contract
- SPE2DR25D1053-SPE2DR26FT873Delivery Order
The Defense Logistics Agency awarded a $14,609.25 delivery order to AmerisourceBergen Drug Corp on November 13, 2025, for the supply of Zeposia 0.92 mg capsules (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation, scheduled for completion by December 5, 2025. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026 that serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, functions as a critical federal medical procurement vendor supplying a comprehensive range of pharmaceutical products and medical supplies to military and veteran healthcare systems. The company has demonstrated significant capability to fulfill federal medical supply requirements through competitive procurement, as evidenced by its extensive portfolio of delivery orders covering diabetes medications, neurological treatments, pain management pharmaceuticals, antibiotics, and specialized medical supplies. Zeposia, an immunosuppressant medication used primarily in the treatment of multiple sclerosis and ulcerative colitis, represents one of the specialized pharmaceutical commodities within AmerisourceBergen's federal delivery capabilities to support Defense Health Agency and other military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.6k | 11/13/25 |